Recent studies have shown that SHARPIN is frequently upregulated in multiple human cancer types, including ovarian, prostate (17), and breast cancers (18), hepatocellular carcinoma (19) and melanoma (20). Here, SHARPIN is linked to hepatocellular carcinoma.